Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study

The retrospective cohort study, utilizing the Spanish primary care database BIFAP, investigated the association between high doses of cyproterone acetate (CPA) and the risk of meningioma. It included 2,474 users of high dose CPA, accounting for 6,663 person-years, and compared them with non-users and low dose CPA users. The study found that high dose CPA users had an incidence rate of meningioma of 60.0 per 100,000 person-years, significantly higher than the 6.6 per 100,000 person-years observed among non-users. After adjusting for age and gender, the incidence rate ratio for high dose CPA users was 11.4 compared to non-users, indicating an increased risk of meningioma, particularly with exposures longer than 1 year. Conversely, no increased risk was detected for women using low doses of CPA. The conclusion was that high dose CPA use is linked to a heightened risk of developing meningioma.